Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.

Abstract

BACKGROUND Adequate infliximab (IFX) levels are associated with favorable outcomes in inflammatory bowel disease. Using therapeutic drug monitoring (TDM) to guide dosing is cost effective and associated with clinical improvement, but effect on endoscopic outcomes remains unclear. METHODS Primary responders to IFX who underwent dose escalation (2008-2014… (More)
DOI: 10.1097/MIB.0000000000001126

Topics

Cite this paper

@article{Kelly2017TherapeuticDM, title={Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.}, author={Orlaith B Kelly and Sarah Oʼ Donnell and Joanne M Stempak and A. Hillary Steinhart and Mark S. Silverberg}, journal={Inflammatory bowel diseases}, year={2017}, volume={23 7}, pages={1202-1209} }